Financial Architects, Inc Crispr Therapeutics Ag Transaction History

Financial Architects, Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$110.72 - $210.04 $221,993 - $421,130	-2,005 Closed	0 $0
Q4 2020 Feb 17, 2021	BUY	$79.67 - $173.23 $159,738 - $347,326	2,005 New	2,005 $307,000
Q3 2020 Nov 09, 2020	SELL	$78.5 - $100.64 $14,208 - $18,215	-181 Closed	0 $0
Q1 2020 May 07, 2020	BUY	$33.68 - $62.53 $6,096 - $11,317	181 New	181 $8,000
Q1 2019 May 03, 2019	SELL	$28.02 - $40.87 $8,406 - $12,261	-300 Closed	0 $0
Q4 2018 Feb 01, 2019	BUY	$22.73 - $42.34 $6,819 - $12,702	300 New	300 $9,000
Q2 2018 Aug 03, 2018	SELL	$42.62 - $73.59 $42,620 - $73,590	-1,000 Closed	0 $0
Q1 2018 Apr 23, 2018	BUY	$23.52 - $58.17 $23,520 - $58,170	1,000 New	1,000 $46,000

491

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.61B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Financial Architects, Inc, based on Form 13F filings with the SEC.

Stay updated on Financial Architects, Inc with notifications on news.